On March 12th, MobiDrop Biotech (Zhejiang) Technology Co., Ltd. (hereinafter referred to as "MobiDrop Bio") and Shenzhen Salus Bio Medical Technology Co., Ltd. (hereinafter referred to as "Salus Medical") reached a strategic cooperation, and Dr. Roy Pei, CEO of MobiDrop Biologics, and Dr. Luyang Zhao, CEO of Salus Medical, signed a contract on behalf of both parties.

Signing site

According to the cooperation agreement, MobiNova® platform will be compatible with Salus Pro, a domestic high-throughput sequencing platform with independent intellectual property rights of Salus Medical. Through their technical advantages and achievements in microfluidics and single cell sequencing, the two parties will jointly build a new molecular diagnostic and life science research platform with higher throughput, higher efficiency, more flexibility and lower cost, further enhance their core competitiveness and industry influence, and provide more powerful technical support for research, drug development and clinical applications.

About Salus Medical

Founded in October 2020, Salus Medical focuses on developing its own upstream sequencing platform and building the world's leading super-resolution spatialomics platform based on it to realize the independent development of genomics and spatialomics products and the translation of research and clinical end. The company has broken through the bottleneck of previous sequencing products in terms of throughput, cost, resolution, automation, etc., and realized the localization of the platform at the same time. Since its establishment, the company has grown rapidly and now has a leading international sequencing and histology platform, which can provide comprehensive solutions for midstream and downstream applications, and has cooperated with many institutions.

About MobiDrop

Founded in Boston, USA and located in Zhejiang, China, MobiDrop is a group of outstanding talents consisting of international top scientists and executives from multinational medical device  companies. We are committed to empowering scientific research and precision medicine with innovative microfluidic and single-cell sequencing technologies. It has become a leader in research+IVD solutions with key technologies such as microfluidics, sequencing, biochemistry, hardware development, and bioconferencing, and has launched a dual technology platform for single-cell sequencing and digital PCR, developing in parallel in multiple fields such as liquid biopsy, companion diagnostics, and life science research.